Grufity logoGrufity logo

Abbott Laboratories Stock Research

ABT

98.05USD+1.01(+1.04%)Market Closed

Market Summary

USD98.05+1.01
Market Closed
1.04%

ABT Alerts

ABT Stock Price

ABT RSI Chart

ABT Valuation

Market Cap

171.9B

Price/Earnings (Trailing)

24.79

Price/Sales (Trailing)

3.94

EV/EBITDA

16.01

Price/Free Cashflow

22.02

ABT Price/Sales (Trailing)

ABT Profitability

EBT Margin

19.03%

Return on Equity

18.9%

Return on Assets

9.31%

Free Cashflow Yield

4.54%

ABT Fundamentals

ABT Revenue

Revenue (TTM)

43.7B

Revenue Y/Y

-12.01%

Revenue Q/Q

-3.06%

ABT Earnings

Earnings (TTM)

6.9B

Earnings Y/Y

-48.06%

Earnings Q/Q

-28.01%

Price Action

52 Week Range

93.25123.22
(Low)(High)

Last 7 days

-1.0%

Last 30 days

-4.5%

Last 90 days

-9.4%

Trailing 12 Months

-15.7%

ABT Financial Health

Current Ratio

1.63

Debt/Equity

0.49

Debt/Cashflow

0.57

ABT Investor Care

Buy Backs (1Y)

1.21%

Diluted EPS (TTM)

3.91

Peers (Alternatives to Abbott Laboratories)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
180.7B
31.5B
-0.78% -13.30%
25.07
5.74
6.85% 12.06%
171.9B
43.7B
-4.52% -15.68%
24.79
3.94
1.34% -1.95%
105.6B
30.8B
-6.73% -24.80%
25.98
3.43
-3.19% -17.38%
89.7B
6.2B
9.79% -8.77%
67.87
14.42
8.97% -22.43%
40.2B
3.4B
1.94% -10.16%
59.26
11.95
4.73% -8.83%
MID-CAP
10.5B
847.1M
5.10% 33.54%
-5.2K
12.36
13.32% -137.89%
3.9B
630.7M
-5.79% -41.33%
-242.52
6.24
25.40% -128.45%
3.7B
-
-3.05% -21.16%
3.27
1.42
- -
SMALL-CAP
1.1B
237.3M
15.32% -32.47%
-24.23
4.63
6.59% 84.02%
958.4M
257.3M
13.67% -32.65%
-48.19
3.72
1.41% -1632.49%
412.1M
71.7M
-0.40% 60.36%
-10.13
5.75
20.17% -128.83%
260.1M
101.9M
-22.22% -55.97%
-8.05
2.55
-3.74% -420.65%
85.6M
-
-4.67% -35.44%
-3.49
801.64
4.35% 34.71%
75.1M
58.0M
-14.05% 3.76%
-8.85
1.3
4.90% -74.98%
2.7M
-
-66.21% -40.16%
-0.05
4.15
- -

Financials for Abbott Laboratories

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue-3.1%43,65345,03045,54844,51443,075
  S&GA Expenses-0.7%11,24811,32311,35911,32811,324
  R&D Expenses-1.3%2,8882,9252,8152,7852,742
Costs and Expenses-0.9%35,29135,59435,33635,28634,650
EBITDA-9.3%10,11811,16011,89710,950-
EBITDA Margin-6.5%0.23*0.25*0.26*0.25*-
Earnings Before Taxes-10.8%8,3069,31310,0489,0448,211
EBT Margin-8.0%0.19*0.21*0.22*0.20*-
Interest Expenses4.3%558535527529533
Net Income-12.1%6,9337,8898,5547,7257,071
Net Income Margin-9.3%0.16*0.18*0.19*0.17*-
Free Cahsflow-8.6%7,8048,5418,4688,152-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets2.2%74,43872,80174,20274,00775,196
  Current Assets1.5%25,22424,84524,95623,42924,239
    Cash Equivalents3.0%9,8829,5948,9377,6759,799
  Inventory7.7%6,1735,7345,8995,6915,157
  Net PPE5.4%9,1628,6898,8188,9088,959
  Goodwill2.3%22,79922,28422,74423,17923,231
  Current Liabilities15.9%15,48913,36512,39212,64713,105
.    Short Term Borrowings------
  Long Term Debt-18,050----
    LT Debt, Current101.5%2,2511,1175.004.00754
    LT Debt, Non Current-5.1%14,52215,29716,75517,08617,296
Shareholder's Equity2.8%36,68635,67536,49035,39935,802
  Retained Earnings0.4%35,25735,11534,48733,29531,528
Accumulated Depreciation4.1%11,05010,61710,64010,61310,405
Shares Outstanding-0.1%1,7531,7541,762--
Minority Interest4.8%219209226230222
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-7.2%9,58110,32210,2439,96110,533
  Share Based Compensation1.3%685676667657640
Cashflow From Investing2.2%-1,740-1,779-1,946-1,946-2,008
Cashflow From Financing5.3%-7,636-8,065-7,899-8,350-5,494
  Dividend Payments0.8%3,3093,2843,2593,2343,202
  Buy Backs-7.1%3,7954,0843,8654,3312,299

Risks for ABT

What is the probability of a big loss on ABT?

36.1%


Probability that Abbott Laboratories stock will be more than 20% underwater in next one year

5%


Probability that Abbott Laboratories stock will be more than 30% underwater in next one year.

0%


Probability that Abbott Laboratories stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ABT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Abbott Laboratories was unfortunately bought at previous high price.

Drawdowns

Returns for ABT

Cumulative Returns on ABT

13.1%


10-Year Cumulative Returns

15.4%


7-Year Cumulative Returns

12.2%


5-Year Cumulative Returns

13.7%


3-Year Cumulative Returns

What are the long-term rolling returns for ABT?

FIve years rolling returns for Abbott Laboratories.

Annualized Returns

Which funds bought or sold ABT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-15
B. Riley Wealth Advisors, Inc.
reduced
-2.48
626,133
6,465,130
0.18%
2023-03-13
Claro Advisors LLC
added
35.55
158,798
589,798
0.19%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-3.34
7,272,550
82,384,600
0.09%
2023-03-10
MATHER GROUP, LLC.
added
14.43
768,634
3,344,630
0.06%
2023-03-08
Pacific Wealth Management
reduced
-2.34
451,513
4,625,510
3.40%
2023-03-08
Capital Asset Advisory Services LLC
added
21.93
458,625
1,619,620
0.13%
2023-03-08
SHEETS SMITH WEALTH MANAGEMENT
reduced
-9.42
11,078
396,078
0.06%
2023-03-07
Great Lakes Retirement, Inc.
new
-
1,099,960
1,099,960
0.28%
2023-03-06
BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL
unchanged
-
334,407
2,819,410
1.07%
2023-03-06
NORTH STAR ASSET MANAGEMENT INC
added
0.87
3,623,700
28,696,700
1.78%

1–10 of 48

Latest Funds Activity

Are funds buying ABT calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own ABT
No. of Funds

Abbott Laboratories News

MarketBeat

Kingfisher Capital LLC Grows Position in Abbott Laboratories (NYSE ....

MarketBeat,
2 minutes ago

MarketWatch

Yahoo Finance

Schedule 13G FIlings of Abbott Laboratories

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
8.92%
155,480,794
SC 13G/A
Feb 06, 2023
blackrock inc.
8.0%
139,526,216
SC 13G/A
Feb 09, 2022
vanguard group inc
8.43%
149,152,264
SC 13G/A
Feb 01, 2022
blackrock inc.
7.8%
137,155,602
SC 13G/A
Feb 16, 2021
capital research global investors
4.9%
86,394,199
SC 13G/A
Feb 10, 2021
vanguard group inc
8.31%
147,272,920
SC 13G/A
Jan 29, 2021
blackrock inc.
7.5%
133,426,810
SC 13G/A
Feb 14, 2020
capital research global investors
6.4%
113,689,293
SC 13G/A
Feb 12, 2020
vanguard group inc
8.58%
151,783,436
SC 13G/A
Feb 05, 2020
blackrock inc.
7.1%
124,728,602
SC 13G/A

ABT Fair Value

Abbott Laboratories fair value in different scenarios

The table shows the Fair Value estimates for Abbott Laboratories for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

-

-

-

-

-

-

-

-

-

-
Current Inflation

70.76

-27.83%

90.64

-7.56%

126.76

29.28%

177.83

81.37%

202.41

106.44%
Very High Inflation

-

-

-

-

-

-

-

-

-

-

Historical Abbott Laboratories Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Abbott Laboratories

View All Filings
Date Filed Form Type Document
Mar 17, 2023
ARS
ARS
Mar 17, 2023
DEF 14A
DEF 14A
Mar 17, 2023
DEFA14A
DEFA14A
Mar 02, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading

Latest Insider Trading transactions for ABT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-01
Ahlberg Gregory A
sold
-132,622
100
-1,317
senior vice president
2023-03-01
Ginascol John F
sold
-94,960
100
-943
executive vice president
2023-03-01
DALE MICHAEL D
sold
-121,746
100
-1,209
senior vice president
2023-03-01
WOODGRIFT RANDEL WILLIAM
sold
-103,922
100
-1,032
senior vice president
2023-03-01
MANNING JOSEPH J
sold
-134,837
100
-1,339
executive vice president
2023-03-01
Salvadori Daniel Gesua Sive
sold
-109,260
100
-1,085
executive vice president
2023-03-01
Tyler Julie L.
sold
-52,867
100
-525
senior vice president
2023-03-01
Moreland Mary K
sold
-72,252
100
-717
executive vice president
2023-03-01
Funck, Jr. Robert E.
sold
-127,285
100
-1,264
executive vice president
2023-03-01
Earnhardt Lisa D
sold
-94,960
100
-943
executive vice president

1–10 of 50

Robert B. Ford
65535
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

ABT Income Statement

2022-12-31
Consolidated Statement of Earnings - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]   
Net Sales$ 43,653$ 43,075$ 34,608
Cost of products sold, excluding amortization of intangible assets19,14218,53715,003
Amortization of intangible assets2,0132,0472,132
Research and development2,8882,7422,420
Selling, general and administrative11,24811,3249,696
Total Operating Cost and Expenses35,29134,65029,251
Operating Earnings8,3628,4255,357
Interest expense558533546
Interest income(183)(43)(46)
Net foreign exchange (gain) loss21(8)
Other (income) expense, net(321)(277)(103)
Earnings from Continuing Operations Before Taxes8,3068,2114,968
Taxes on Earnings from Continuing Operations1,3731,140497
Earnings from Continuing Operations6,9337,0714,471
Net Earnings from Discontinued Operations, net of taxes0024
Net Earnings$ 6,933$ 7,071$ 4,495
Basic Earnings Per Common Share --   
Continuing Operations (in dollars per share)$ 3.94$ 3.97$ 2.51
Discontinued Operations (in dollars per share)000.01
Net Earnings (in dollars per share)3.943.972.52
Diluted Earnings Per Common Share --   
Continuing Operations (in dollars per share)3.913.942.49
Discontinued Operations (in dollars per share)000.01
Net Earnings (in dollars per share)$ 3.91$ 3.94$ 2.50
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares)1,7531,7751,773
Dilutive Common Stock Options (in shares)111413
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares)1,7641,7891,786
Outstanding Common Stock Options Having No Dilutive Effect (in shares)309

ABT Balance Sheet

2022-12-31
Consolidated Balance Sheet - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 9,882$ 9,799
Investments, primarily bank time deposits and U.S. treasury bills288450
Trade receivables, less allowances of — 2022: $500; 2021: $5196,2186,487
Inventories:  
Finished products3,8053,081
Work in process680694
Materials1,6881,382
Total inventories6,1735,157
Other prepaid expenses and receivables2,6632,346
Total current assets25,22424,239
Investments766816
Property and equipment, at cost:  
Land511525
Buildings4,0534,007
Equipment14,16413,528
Construction in progress1,4841,304
Property and equipment, at cost20,21219,364
Less: accumulated depreciation and amortization11,05010,405
Net property and equipment9,1628,959
Intangible assets, net of amortization10,45412,739
Goodwill22,79923,231
Deferred income taxes and other assets6,0335,212
Total Assets74,43875,196
Current liabilities:  
Trade accounts payable4,6074,408
Salaries, wages and commissions1,5561,625
Other accrued liabilities5,8455,181
Dividends payable887831
Income taxes payable343306
Current portion of long-term debt2,251754
Total current liabilities15,48913,105
Long-term debt14,52217,296
Post-employment obligations and other long-term liabilities7,5228,771
Commitments and contingencies
Shareholders’ investment:  
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued00
Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2022: 1,986,519,278; 2021: 1,985,273,42124,70924,470
Common shares held in treasury, at cost — Shares: 2022: 248,724,257; 2021: 221,191,228(15,229)(11,822)
Earnings employed in the business35,25731,528
Accumulated other comprehensive income (loss)(8,051)(8,374)
Total Abbott Shareholders’ Investment36,68635,802
Noncontrolling interests in subsidiaries219222
Total Shareholders’ Investment36,90536,024
Total Liabilities and Shareholders' Investment$ 74,438$ 75,196